Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Fondaparinux plus vitamin K antagonist vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.93 [0.45, 1.91]
2 studies · 2645 participants
Moderate

Direct thrombin inhibitors vs vitamin K antagonist (VKA)

All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).

1 finding from 1 review

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
OR 1.62 [0.57, 4.58]
3 studies · 5243 participants
Low

Direct thrombin inhibitors vs low molecular weight heparin

All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).

1 finding from 1 review

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
OR 2.06 [1.1, 3.87]
11 studies · 22065 participants
Moderate